Gsk (GLAXF) Liabilities and Shareholders Equity (2009 - 2026)

Gsk's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $84.8 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 10.86% year-over-year to $84.8 billion; the TTM figure through Mar 2026 stood at $327.9 billion (up 8.75% YoY), while the FY2025 annual figure was $80.6 billion, up 6.02% from the prior year.
• Liabilities and Shareholders Equity was $84.8 billion for Q1 2026 at Gsk, up from $81.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $112.1 billion in Q2 2022 to a low of $60.4 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $77.3 billion across 5 years, with a median of $75.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity plunged 43.89% in 2022, then rose 17.89% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $70.5 billion in 2022, then climbed by 3.81% to $73.2 billion in 2023, then rose by 4.21% to $76.3 billion in 2024, then grew by 6.52% to $81.3 billion in 2025, then rose by 4.26% to $84.8 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $84.8 billion (Q1 2026), $81.3 billion (Q4 2025), and $82.8 billion (Q3 2025), per Business Quant data.